Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Read full text Summarise with VIRAT
Authors: Jie Ma, Caie Li, Wenjuan Wang, Xin Fan, T A O T A O Wei, Xin Ma, Yingdong Wang, Chuyan Feng, Jing Yu
Cited by: 0
References: 91

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including deoxyribonucleic acid (DNA) repair, apoptosis, protein synthesis, cellular proliferation, and responses to oxidative stress. PARP inhibitors (PARPIs) exhibit selective cytotoxicity in cancers with breast cancer susceptibility gene (BRCA) mutations or defects in homologous recombination. Activation of PARP, indicated by increased poly(ADP-ribose) (PAR) accumulation, is implicated in various disease states such as ischemia-reperfusion injury, vascular disorders, and diabetic complications. Clinically, PARPIs, in combination with anti-angiogenic therapies, not only show efficacy as monotherapies in epithelial ovarian cancer but also mitigate hypertension induced by anti-angiogenic agents. This review consolidates recent advancements in understanding the dual therapeutic potential of PARP inhibition, encompassing both antineoplastic and cardioprotective effects.

Fields of Study & Subjects

PARP inhibition in cancer therapy Angiogenesis and VEGF in Cancer Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
Reviews in Cardiovascular Medicine
Volume
27
Issue
3
Pages
44942–44942
Publication date
12 March 2026
Language
EN